Demographic Profile of Drug-Resistant Tuberculosis Patients

Ricky Fernando Adi; Yeni  Jamilah; Rima  Melati

doi:10.37899/journallamedihealtico.v6i3.2035

Ricky Fernando Adi Faculty of Medicine, President University, Indonesia
Yeni Jamilah Regency Bekasi Regional General Hospital, Indonesia
Rima Melati Faculty of Medicine, President University, Indonesia

DOI: https://doi.org/10.37899/journallamedihealtico.v6i3.2035

Keywords: Drug-Resistant Tuberculosis, Demographic Epidemiology, Public Health, Infection Control

Abstract

Drug-Resistant Tuberculosis (DR-TB) represents a significant global health challenge with complex treatment and control issues. In Bekasi Regency, a metropolitan area with high population density, DR-TB incidence shows an increase requiring special attention. This study aims to identify the demographic profile of DR-TB patients to understand disease distribution characteristics and design appropriate management strategies. A descriptive study conducted at Bekasi Regency Hospital from October 2022 to October 2024. Data collected through MDR-TB outpatient medical records identified via Molecular Quick Test. Variables studied included age, gender, district of residence, and education level. Data analyzed using descriptive statistics and presented in tables, diagrams, and graphs. Among 338 DR-TB patients, the majority were aged 41-50 years (27.1%), with male patient dominance (61.5%). Tambun Selatan District had the highest cases (16.9%), with a population density of 10,063 people/km². Most patients were high school graduates (74.3%), with 89.6% originating from Bekasi Regency. The demographic profile of DR-TB patients at Bekasi Regency Hospital shows patterns similar to general tuberculosis cases. Tambun Selatan District exhibits the highest spread risk, indicating the need for targeted interventions in DR-TB prevention and control.

References

Al-Worafi, Y. M. (2023). Tuberculosis Management in Developing Countries. In Handbook of Medical and Health Sciences in Developing Countries: Education, Practice, and Research (pp. 1-40). Cham: Springer International Publishing. http://dx.doi.org/10.1007/978-3-030-74786-2_52-1

Ambaw, F., Mayston, R., Hanlon, C., Medhin, G., & Alem, A. (2018). Untreated depression and tuberculosis treatment outcomes, quality of life and disability, Ethiopia. Bulletin of the World Health Organization, 96(4), 243. https://doi.org/10.2471/BLT.17.192658

Badan Pusat Statistik Provinsi Jawa Barat. (2023). Kasus Penyakit Menurut Kabupaten/Kota dan Jenis Penyakit di Provinsi Jawa Barat, 2023. Badan Pusat Statistik Provinsi Jawa Barat.

Borah, P., Deb, P. K., Venugopala, K. N., Al-Shar'i, N. A., Singh, V., Deka, S., ... & Mailavaram, R. P. (2021). Tuberculosis: an update on pathophysiology, molecular mechanisms of drug resistance, newer anti-TB drugs, treatment regimens and host-directed therapies. Current Topics in Medicinal Chemistry, 21(6), 547-570. https://doi.org/10.2174/1568026621999201211200447

Dinas Kependudukan dan Pencatatan Sipil Kabupaten Bekasi. (2024). Profil perkembangan kependudukan Kabupaten Bekasi tahun 2023. Bekasi, Indonesia: Pemerintah Kabupaten Bekasi.

Direktorat Jenderal Bina Upaya Kesehatan Direktorat Jenderal Pengendalian Penyakit dan Kesehatan Lingkungan. (2012). Petunjuk teknis pemeriksaan biakan, identifikasi, dan uji kepekaan Mycobacterium tuberculosis pada media padat. In Jakarta: Kementerian Kesehatan RI.

Direktorat Jenderal Pencegahan dan Pengendalian Penyakit. Direktorat Pencegahan dan Pengendalian Penyakit Menular. (2023). Laporan program penanggulangan tuberkulosis tahun 2022. Jakarta: Kementerian Kesehatan RI.

Doe, J., Smith, L., & Lee, H. (2020). Risk factors for multidrug-resistant tuberculosis: A systematic review and meta-analysis. Journal of Infectious Diseases, 221(1), 81–91. https://doi.org/10.1371/journal.pone.0270003

Engel, N., Ochodo, E. A., Karanja, P. W., Schmidt, B. M., Janssen, R., Steingart, K. R., & Oliver, S. (2022). Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views. Cochrane Database of Systematic Reviews, (4). https://doi.org/10.1002/14651858.cd014877.pub2

Handayani, R. S., Hendarwan, H., & Ratri, T. (2024). The Influence of Medication Non-Adherence on the Occurrence of Drug-Resistant Tuberculosis. Journal of Current Health Sciences, 4(2), 59-66. https://doi.org/10.47679/jchs.202474

Harries, A. D., Kumar, A. M., Satyanarayana, S., Takarinda, K. C., Timire, C., & Dlodlo, R. A. (2020). Treatment for latent tuberculosis infection in low-and middle-income countries: progress and challenges with implementation and scale-up. Expert review of respiratory medicine, 14(2), 195-208. https://doi.org/10.1080/17476348.2020.1694907

Johnston, J. C., Cooper, R., & Menzies, D. (2022). Chapter 5: Treatment of tuberculosis disease. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 6(sup1), 66-76. https://doi.org/10.1080/24745332.2022.2036504

Kementerian Kesehatan Republik Indonesia. (2020). Strategi Nasional Penanggulangan Tuberkulosis di Indonesia 2020-2024. Pertemuan Konsolidasi Nasional Penyusunan STRANAS TB, 135.

Matteelli, A., Centis, R., D’Ambrosio, L., Sotgiu, G., Tadolini, M., Pontali, E., ... & Migliori, G. B. (2016). WHO strategies for the programmatic management of drug-resistant tuberculosis. Expert review of respiratory medicine, 10(9), 991-1002. https://doi.org/10.1080/17476348.2016.1199278

Monde, N., Munyeme, M., Chongwe, G., Wensman, J. J., Zulu, M., Siziya, S., ... & Malama, S. (2023). First and second-line anti-tuberculosis drug-resistance patterns in pulmonary tuberculosis patients in Zambia. Antibiotics, 12(1), 166. https://doi.org/10.3390/antibiotics12010166

Müller, A. M., Osório, C. S., Silva, D. R., Sbruzzi, G., De Tarso, P., & Dalcin, R. (2018). Interventions to improve adherence to tuberculosis treatment: systematic review and meta-analysis. The International Journal of Tuberculosis and Lung Disease, 22(7), 731–740. https://doi.org/10.5588/ijtld.17.0596

Nair, S. A., Raizada, N., Sachdeva, K. S., Denkinger, C., Schumacher, S., Dewan, P., Kulsange, S., Boehme, C., Paramsivan, C. N., & Arinaminpathy, N. (2016). Factors associated with tuberculosis and rifampicin-resistant tuberculosis amongst symptomatic patients in India: a retrospective analysis. PLoS One, 11(2), e0150054. https://doi.org/10.1371/journal.pone.0150054

Nugroho, K. B. C., & Sasanti, R. R. (2025). A Comprehensive Literature Review of Mycobacterium tuberculosis Drug Resistance. The International Journal of Medical Science and Health Research, 10(6), 1-45. http://dx.doi.org/10.70070/9a8dvp05

Otto-Knapp, R., Bauer, T., Brinkmann, F., Feiterna-Sperling, C., Friesen, I., Geerdes-Fenge, H., ... & Schaberg, T. (2024). Treatment of MDR, pre-XDR, XDR, and rifampicin-resistant tuberculosis or in case of intolerance to at least rifampicin in Austria, Germany, and Switzerland. Respiration, 103(9), 593-600. https://doi.org/10.1159/000539410

Prasad, R., Singh, A., & Gupta, N. (2021). Adverse drug reactions with first-line and second-line drugs in treatment of tuberculosis. Annals of the National Academy of Medical Sciences (India), 57(01), 15-35. https://doi.org/10.1055/s-0040-1722535

Rahman, M. M., Alam Tumpa, M. A., Zehravi, M., Sarker, M. T., Yamin, M. D., Islam, M. R., Harun-Or-Rashid, M., Ahmed, M., Ramproshad, S., & Mondal, B. (2022). An overview of antimicrobial stewardship optimization: the use of antibiotics in humans and animals to prevent resistance. Antibiotics, 11(5), 667. https://doi.org/10.3390/antibiotics13040353

Reddy, K. P., Brady, M. F., Gilman, R. H., Coronel, J., Navincopa, M., Ticona, E., Chavez, G., Sańchez, E., Rojas, C., & Solari, L. (2010). Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons. Clinical Infectious Diseases, 50(7), 988–996. https://doi.org/10.1086/651081

Rossi, I., Bettini, R., & Buttini, F. (2021). Resistant tuberculosis: the latest advancements of second-line antibiotic inhalation products. Current Pharmaceutical Design, 27(12), 1436-1452. https://doi.org/10.2174/1381612827666210122143214

Saktiawati, A. M. I., Vasiliu, A., Saluzzo, F., & Akkerman, O. W. (2024). Strategies to Enhance Diagnostic Capabilities for the New Drug-Resistant Tuberculosis (DR-TB) Drugs. Pathogens, 13(12), 1045. https://doi.org/10.3390/pathogens13121045

Shah, M., Dansky, Z., Nathavitharana, R., Behm, H., Brown, S., Dov, L., ... & Burzynski, J. (2024). National Tuberculosis Coalition of America (NTCA) guidelines for respiratory isolation and restrictions to reduce transmission of pulmonary tuberculosis in community settings. Clinical Infectious Diseases, ciae199. https://doi.org/10.1093/cid/ciae199

Suman, S. K., Chandrasekaran, N., & Priya Doss, C. G. (2023). Micro-nanoemulsion and nanoparticle-assisted drug delivery against drug-resistant tuberculosis: recent developments. Clinical Microbiology Reviews, 36(4), e00088-23. https://doi.org/10.1128/cmr.00088-23

Vigenschow, A. (2019). Structured assessment of healthcare facilities and knowledge, attitudes and practices of healthcare workers regarding tuberculosis infection control in Moyen-Ogooué, Gabon (Doctoral dissertation, Universität Tübingen).

Whittaker, E., López-Varela, E., Broderick, C., & Seddon, J. A. (2019). Examining the complex relationship between tuberculosis and other infectious diseases in children. Frontiers in Pediatrics, 7, 233. https://doi.org/10.3389/fped.2019.00233

World Health Organization. (2023). Global tuberculosis report 2023. Geneva, Switzerland: WHO.

Wulandari, D. A., Hartati, Y. W., Ibrahim, A. U., & Pitaloka, D. A. E. (2024). Multidrug-resistant tuberculosis. Clinica Chimica Acta, 559, 119701. https://doi.org/10.1016/j.cca.2024.119701